Clinical Trials
60 trialsNCT07593079 2026-05-18
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT00544830 2026-05-15
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07455903 2026-05-13
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Recruiting
NCT01251861 2026-04-29
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01786265 2026-02-20
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07393867 2026-02-06
ARPEGGIO
Brigham and Women's Hospital
Phase 2 Not yet recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT03809000 2025-12-30
STEEL
RTOG Foundation, Inc.
Phase 2 Active not recruiting
NCT05327647 2025-12-18
BicaBCa
CHU de Quebec-Universite Laval
Phase 2 Recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT01288911 2024-12-06
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
Phase 2 Completed
NCT03141671 2024-05-14
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06018116 2024-02-15
CANUCK-01
CHU de Quebec-Universite Laval
Phase 2 Withdrawn
NCT00866554 2023-06-02
Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy
CHU de Quebec-Universite Laval
Phase 2 Completed
NCT00771017 2023-05-25
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT02058706 2023-05-10
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02582749 2022-07-11
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02614859 2022-03-29
BIMET-1
Fox Chase Cancer Center
Phase 2 Completed
NCT03541928 2021-04-06
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
The Methodist Hospital Research Institute
Phase 2 Unknown
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02742675 2020-07-07
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
Fudan University
Phase 2 Unknown
NCT00528866 2019-04-24
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01664923 2019-01-30
STRIVE
Pfizer
Phase 2 Completed
NCT03147196 2019-01-22
Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Mayo Clinic
Phase 2 Withdrawn
NCT00298155 2018-08-09
TAPS
University of Washington
Phase 2 Completed
NCT00283803 2018-08-07
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Phase 2 Completed
NCT00165399 2018-06-25
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01120236 2018-02-26
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00814788 2018-01-10
UCDCC#215
University of California, Davis
Phase 2 Completed
NCT00630344 2017-12-08
RAD001 and Bicalutamide for Androgen Independent Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01200810 2017-12-02
Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00589472 2017-10-06
TARGET
National Cancer Institute (NCI)
Phase 2 Completed
NCT00658697 2017-05-25
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00486642 2017-05-24
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00170157 2017-05-15
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT00769795 2017-03-29
Study of Effectiveness of IMC-A12 Antibody Combined With Hormone Therapy Prior to Surgery to Treat Prostate Cancer
University of Washington
Phase 2 Completed
NCT00659438 2016-12-05
Efficacy and Safety of Zactimaâ„¢ in Patients With Castration-refractory Metastatic Prostate Cancer
Sanofi
Phase 2 Completed
NCT00776594 2016-10-21
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02678520 2016-07-22
Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients
University of Kansas Medical Center
Phase 2 Withdrawn
NCT01658527 2016-06-10
TAK-700 in Castration Resistant Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT00521781 2016-03-17
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT01674270 2015-12-22
Degarelix Neo-Adjuvant Radical Prostatectomy Trial
University Health Network, Toronto
Phase 2 Completed
NCT00108732 2015-06-30
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00666666 2014-12-18
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01531205 2014-11-05
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00349557 2014-07-16
Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer
Benaroya Research Institute
Phase 2 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed